Format

Send to

Choose Destination
See comment in PubMed Commons below
Infect Control Hosp Epidemiol. 2002 Feb;23(2):87-90.

Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine.

Author information

  • 1Infection Management Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Abstract

OBJECTIVE:

To study the humoral immune responses, safety, and tolerability of intradermal recombinant hepatitis B vaccination in healthcare workers (HCWs) nonresponsive to previous repeated intramuscular vaccination.

DESIGN:

An open, prospective, before-after trial.

SETTING:

A tertiary referral hospital and surrounding district health service in Queensland, Australia.

PARTICIPANTS:

Hospital and community HCWs nonresponsive to previous intramuscular hepatitis B vaccination.

METHODS:

Intradermal recombinant hepatitis B vaccine was administered every second week for a maximum of 4 doses. Hepatitis B surface antibody (anti-HBs) responses were assessed 2 weeks after each dose.

RESULTS:

Protective anti-HBs levels developed in 17 (94%) of 18 study subjects. Three doses resulted in seroconversion of all responding subjects and the highest geometric mean antibody concentration. The vaccine was well tolerated.

CONCLUSION:

More than 90% of previously nonresponsive HCWs responded to intradermal recombinant hepatitis B vaccine with protective anti-HBs levels.

PMID:
11894838
DOI:
10.1086/502012
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Cambridge University Press
    Loading ...
    Support Center